Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk
The U.S. Court of Appeals for the Federal Circuit recently affirmed a $70 million jury award for infringement of a manufacturing process patent for a biosimilar product without any infringing sales....To view the full article, register now.
Already a subscriber? Click here to view full article